CannaPharmaRX, Inc. (CPMD) Fair Value 2026

CPMD · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-27, CannaPharmaRX, Inc. (CPMD) trades at $0.00. QOC: 4.6/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
CPMD
Price
$0.00
Quality Score
4.6/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +234.3% upside with 33% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CPMD?

1 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.01 +234.3%

All Models Active

All 1 models are displayed above.

What Is CannaPharmaRX, Inc. (CPMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, CannaPharmaRX, Inc.'s intrinsic value is estimated at a median fair value of $0.01. At a current market price of $0.00, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +234.3%.

What Do the Models Say About CPMD?

1 of 13 models are currently active for CPMD. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CPMD Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, CPMD ranks #88 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

CannaPharmaRX, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is CPMD a Value Trap?

CirclFi's Value Trap algorithm assigns CPMD a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for CannaPharmaRX, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, CannaPharmaRX, Inc. earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CPMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CPMD's 1 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CannaPharmaRX, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

PNXPPineapple Express Cannabis CompanyQOC 4.7RAPHRaphael Pharmaceutical Inc.QOC 4.6PRFXPRF Technologies Ltd.QOC 4.7CPHIChina Pharma Holdings, Inc.QOC 4.6PLNHPlanet 13 Holdings Inc.QOC 4.7BSPKBespoke Extracts, Inc.QOC 4.5NBIXNeurocrine Biosciences, Inc.QOC 9.1HROWHarrow, Inc.QOC 7.0TLRYTilray Brands, Inc.QOC 5.9UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: PNXP · RAPH · PRFX · CPHI · PLNH · BSPK · NBIX · HROW · TLRY · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CPMD?

6 companies across all industries closest to CPMD’s Quality of Company score of 4.6/10.

BHKBlackRock Core Bond TrustQOC 4.6BSAIBluSky AI, Inc.QOC 4.6KAVLKaival Brands Innovations Group, Inc.QOC 4.6IRONDisc Medicine, Inc.QOC 4.6LTRNLantern Pharma Inc.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BHK · BSAI · KAVL · IRON · LTRN · NVDA

Where Does CPMD Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CPMD is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About CannaPharmaRX, Inc.’s Valuation?

What is CannaPharmaRX, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for CannaPharmaRX, Inc. (CPMD). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CPMD overvalued or undervalued right now?

At $0.00, 1 of 1 active models suggest CPMD may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits CannaPharmaRX, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 4.6 mean for CPMD?

CannaPharmaRX, Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CPMD?

CirclFi analyzes CPMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CPMD a value trap in 2026?

CannaPharmaRX, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns CannaPharmaRX, Inc. (CPMD) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/CPMD/ · Methodology
Primary sources for this CPMD valuation
  • Financial statements: CannaPharmaRX, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001081938) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CPMD as of ; valuations recomputed .